Heeman, Fiona http://orcid.org/0000-0001-7769-8329
,
Yaqub, Maqsood http://orcid.org/0000-0001-6738-2742
Lopes Alves, Isadora
Heurling, Kerstin http://orcid.org/0000-0001-8497-9612
Berkhof, Johannes
Gispert, Juan Domingo http://orcid.org/0000-0002-6155-0642
Bullich, Santiago
Foley, Christopher http://orcid.org/0000-0002-7319-2539
Lammertsma, Adriaan A. http://orcid.org/0000-0003-1237-2891
Funding for this research was provided by:
Innovative Medicines Initiative (115952)
Ramón y Cajal (RYC-2013-13054)
Article History
Received: 30 November 2018
Accepted: 11 March 2019
First Online: 27 March 2019
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study[CitationRef removed, CitationRef removed]. The Ethical Committee of the University Hospitals Leuven approved the study protocol for the [<sup>18</sup>F]flutemetamol study [CitationRef removed, CitationRef removed]. Local Institutional Review Board of University of Leipzig, the National Radiation Safety Committee, and the German Federal Institute for Drugs and Medical Devices approved the study protocol for the [<sup>18</sup>F]florbetaben study [CitationRef removed, CitationRef removed].
: All participants included in this study provided consent for publication.
: CF is employed by GE Healthcare and SB by Life Molecular Imaging GmbH. All other authors declare that they have no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.